1. Home
  2. SCS vs MESO Comparison

SCS vs MESO Comparison

Compare SCS & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SCS
  • MESO
  • Stock Information
  • Founded
  • SCS 1912
  • MESO 2004
  • Country
  • SCS United States
  • MESO Australia
  • Employees
  • SCS N/A
  • MESO N/A
  • Industry
  • SCS Office Equipment/Supplies/Services
  • MESO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SCS Consumer Discretionary
  • MESO Health Care
  • Exchange
  • SCS Nasdaq
  • MESO Nasdaq
  • Market Cap
  • SCS 1.8B
  • MESO 2.0B
  • IPO Year
  • SCS 1998
  • MESO N/A
  • Fundamental
  • Price
  • SCS $15.83
  • MESO $15.67
  • Analyst Decision
  • SCS
  • MESO Buy
  • Analyst Count
  • SCS 0
  • MESO 2
  • Target Price
  • SCS N/A
  • MESO $24.00
  • AVG Volume (30 Days)
  • SCS 1.3M
  • MESO 176.6K
  • Earning Date
  • SCS 12-17-2025
  • MESO 08-28-2025
  • Dividend Yield
  • SCS 2.54%
  • MESO N/A
  • EPS Growth
  • SCS N/A
  • MESO N/A
  • EPS
  • SCS 0.81
  • MESO N/A
  • Revenue
  • SCS $3,259,000,000.00
  • MESO $17,198,000.00
  • Revenue This Year
  • SCS $5.09
  • MESO $440.77
  • Revenue Next Year
  • SCS $2.83
  • MESO $110.74
  • P/E Ratio
  • SCS $19.53
  • MESO N/A
  • Revenue Growth
  • SCS 3.92
  • MESO 191.39
  • 52 Week Low
  • SCS $9.32
  • MESO $9.61
  • 52 Week High
  • SCS $17.40
  • MESO $22.00
  • Technical
  • Relative Strength Index (RSI)
  • SCS 35.24
  • MESO 44.18
  • Support Level
  • SCS $15.63
  • MESO $14.10
  • Resistance Level
  • SCS $15.97
  • MESO $16.91
  • Average True Range (ATR)
  • SCS 0.27
  • MESO 0.42
  • MACD
  • SCS -0.06
  • MESO -0.16
  • Stochastic Oscillator
  • SCS 12.20
  • MESO 50.00

About SCS Steelcase Inc.

Steelcase Inc is a furniture company based in the United States. Its brands, such as Steelcase, AMQ, Coalesse, Designtex, and others, offer a portfolio of furniture and architectural products and services designed to help customers create workplaces. It markets its products and services to businesses and organizations predominantly through a network of dealers and also sells to consumers in markets around the world through web-based and retail distribution channels. The company's reportable segments include the Americas, which generates key revenue, and the International segment.

About MESO Mesoblast Limited

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Share on Social Networks: